Praziquantel + Pyrantel Pamoate + Febantel

Verify with FDA CVM →

164 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
164
Total Reports
6
Deaths Reported
370.0%
Death Rate

Active Ingredients

Praziquantel + Pyrantel Pamoate + Febantel

Administration Routes

OralUnknown

Species Affected

Dog 161
Cat 3

Most Affected Breeds

Retriever - Labrador 16
Crossbred Canine/dog 12
Shepherd Dog - Australian 10
Greyhound 8
Shepherd Dog - German 7
Spitz - German Pomeranian 5
Retriever - Golden 5
Collie - Border 4
Maltese 4
Terrier (unspecified) 4

Most Reported Reactions

Vomiting 44
Emesis 35
Lethargy (see also Central nervous system depression in 'Neurological') 17
INEFFECTIVE, HOOKS 16
Lack of efficacy (endoparasite) - hookworm 13
Other abnormal test result NOS 12
Diarrhoea 11
Lack of efficacy - NOS 10
Not eating 9
Lack of efficacy (endoparasite) - tapeworm 8
Behavioural disorder NOS 7
Lack of efficacy (tapeworm) 6

Outcome Breakdown

Recovered/Normal
78 (47.3%)
Outcome Unknown
54 (32.7%)
Ongoing
16 (9.7%)
Recovered with Sequela
11 (6.7%)
Died
4 (2.4%)
Euthanized
2 (1.2%)

Data Summary

Metric Value
Total adverse event reports 164
Reports involving death 6
Case-fatality rate (reported events) 370.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Praziquantel + Pyrantel Pamoate + Febantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 164 adverse event reports referencing Praziquantel + Pyrantel Pamoate + Febantel, including 6 reports in which the animal died — a 370.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Praziquantel + Pyrantel Pamoate + Febantel. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Praziquantel + Pyrantel Pamoate + Febantel reports are Dog (161 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (16), Crossbred Canine/dog (12), Shepherd Dog - Australian (10) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Praziquantel + Pyrantel Pamoate + Febantel are Vomiting (44), Emesis (35), Lethargy (see also Central nervous system depression in 'Neurological') (17), INEFFECTIVE, HOOKS (16). Of the 165 reports with a coded outcome, Recovered/Normal is the leading category at 47.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Praziquantel + Pyrantel Pamoate + Febantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial